Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which radiation boost is better for prostate cancer? new trial aims to find out

NCT ID NCT01936883

Disease control Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This trial compares two types of brachytherapy boost (HDR vs LDR) given alongside external beam radiation for intermediate- and high-risk prostate cancer. The goal is to see which one provides better cancer control and quality of life with fewer side effects. About 195 men are taking part, and researchers are tracking their urinary, bowel, and sexual function over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation (brachytherapy boost)
What this could lead to
If HDR brachytherapy works better, it could offer similar cancer control with fewer side effects and better quality of life for men with prostate cancer.
What could go wrong
This is a mid-sized trial (195 people) comparing two established treatments, so major breakthroughs are unlikely. Results may not apply to all prostate cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

195 people

The number who actually took part.

Start date

Jan 2014

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Upper tier intermediate risk with at least 2 of the following factors 1. Tumor-Nodes-Metastases Tumor stage T2B or greater 2. Gleason Score 7 3. PSA \> 10 4. \> 50% of the biopsies positive * OR High risk prostate cancer with one of the following factors 1. T3a 2. Gleason Score8-10 3. PSA \>20 * Positive prostate biopsy within 12 months (reviewed centrally) * International Prostate Symptom Score \< 16 * Prostate volume \< 60 cc * Negative staging CT and Bone scan within 3 months prior to registration * History and physical examination within 90 days prior to registration * European Cooperative Oncology Group performance status 0-1 prior to registration * Age \>45 * Patient suitable for procedure under anesthesia Exclusion Criteria: * Prior invasive malignancy (except non melanoma skin cancer) unless disease-free for at least 3 years prior to registration * Previous prostatectomy, cryotherapy or High Intensity Focussed Ultrasound for prostate cancer * Previous pelvic irradiation or prostate brachytherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • British Columbia Cancer Agency Center for the Southern Interior

    Kelowna, British Columbia, V1Y5L3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.